A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 175 of the 176 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system (CNS) leading to mental deterioration and devastation, and eventually a fatal outcome. AD affects mostly the elderly. AD is frequently accompanied by hypercholesterolemia, hypertension, atherosclerosis, and diabetes mellitus, and these are significant risk factors of AD. Other conditions triggered by the progression of AD include psychosis, sleep disorders, epilepsy, and depression. One important comorbidity is Down’s syndrome, which directly contributes to the severity and rapid progression of AD. The development of new therapeutic strategies for AD includes the repurposing of drugs currently used for the treatment of comorbidities. A better understanding of the influence of comorbidities on the pathogenesis of AD, and the medications used in its treatment, might allow better control of disease progression, and more effective pharmacotherapy. Graphic abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Insulin resistance can lead to a disruption in glucose transport and then to weakened glucose metabolism; together, they are thought to cause neurodegeneration in AD [85].”
From Primary Cilia and Cardiovascular Risk Factors in Alzheimer's Disease (2025) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
(2015) · HAL · Cited by 2,238
World Alzheimer Report 2018: The state of the art of dementia research: New frontiers
Patterson, C. (2018) · Cited by 1,461
Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
Iadecola, C., Yaffe, K., Biller, J., Bratzke, L. C., Faraci, F. M., Gorelick, P. B., Gulati, M., Kamel, H., Knopman, D. S., Launer, L. J., et al. (2016) · Hypertension · doi:10.1161/hyp.0000000000000053 · Cited by 746
Epilepsy and Cognitive Impairments in Alzheimer Disease
Palop, J. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.15 · Cited by 684
Amyloid β-Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy
Minkeviciene, R., Rheims, S., Dobszay, M. B., Zilberter, M., Hartikainen, J., Fülöp, L., Penke, B., Zilberter, Y., Harkany, T., Pitkänen, A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5215-08.2009 · Cited by 652
Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., Frangakis, C., Ismail, Z., Marano, C., Meinert, C. L., Mintzer, J. E., Munro, C. A., et al. (2014) · JAMA · doi:10.1001/jama.2014.93 · Cited by 572
Drug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Farzadfar, F., Finucane, M. M., Danaei, G., Pelizzari, P. M., Cowan, M. J., Paciorek, C. J., Singh, G. M., Lin, J. K., Stevens, G. A., Riley, L. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62038-7 · Cited by 513
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Body Mass Index in Midlife and Risk of Alzheimer Disease and Vascular Dementia
Whitmer, R., Gunderson, E., Quesenberry, C., Zhou, J., & Yaffe, K. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362047 · Cited by 430
Forlenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., & Gattaz, W. F. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.080044 · Cited by 402
Craft, S., Raman, R., Chow, T. W., Rafii, M. S., Sun, C.-K., Rissman, R. A., Donohue, M. C., Brewer, J. B., Jenkins, C., Harless, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1840 · Cited by 389
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 365
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
How does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
Molecular Basis of Familial and Sporadic Alzheimer's Disease
Dorszewska, J., Prendecki, M., Oczkowska, A., Dezor, M., & Kozubski, W. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160314150501 · Cited by 329
Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease
Weinshenker, D. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.01.010 · Cited by 323
Executive function in adolescents with Down Syndrome
Lanfranchi, S., Jerman, O., Dal Pont, E., Alberti, A., & Vianello, R. (2010) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2010.01262.x · Cited by 308
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285 · cited 2×
“However, an updated Cochrane review of double‐blind, randomized, placebo‐controlled trials where statins were administered for at least 12 months found them not to prevent dementia or cognitive decline in individuals at high vascular risk in late life [77, 78].”
BackgroundVigen, C. L. P., Mack, W. J., Keefe, R. S. E., Sano, M., Sultzer, D. L., Stroup, T. S., Dagerman, K. S., Hsiao, J. K., Lebowitz, B. D., Lyketsos, C. G., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.08121844 · Cited by 281
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270
The Emerging Link between O-GlcNAc and Alzheimer Disease
Zhu, Y., Shan, X., Yuzwa, S. A., & Vocadlo, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.601351 · Cited by 267
Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias
Yarchoan, M., Xie, S. X., Kling, M. A., Toledo, J. B., Wolk, D. A., Lee, E. B., Van Deerlin, V., Lee, V. M. Y., Trojanowski, J. Q., & Arnold, S. E. (2012) · Brain · doi:10.1093/brain/aws271 · Cited by 262
The Impact of Disease Comorbidities in Alzheimer’s Disease
Santiago, J. A., & Potashkin, J. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.631770 · Cited by 259
Ungar, L., Altmann, A., & Greicius, M. D. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9272-x · Cited by 246
Does vascular pathology contribute to Alzheimer changes?
Kalaria, R. N., Akinyemi, R., & Ihara, M. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.07.032 · Cited by 239
Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of aging cohort
Dolan, H., Crain, B., Troncoso, J., Resnick, S. M., Zonderman, A. B., & Obrien, R. J. (2010) · Annals of Neurology · doi:10.1002/ana.22055 · Cited by 231
Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis
Wilcock, D. M., & Griffin, W. S. T. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-84 · Cited by 230
Seizures and Epilepsy in Alzheimer's Disease
Friedman, D., Honig, L. S., & Scarmeas, N. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00251.x · Cited by 229
The Epidemiology and Impact of Dementia - Current State and Future Trends. WHO Thematic Briefing
Prince, M. J., Guerchet, M., & Prina, M. A. (2015) · Research Portal (King's College London) · Cited by 220
Sleep disorders in aging and dementia
Bombois, S., Derambure, P., Pasquier, F., & Monaca, C. (2010) · The Journal of nutrition, health and aging · doi:10.1007/s12603-010-0052-7 · Cited by 217
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Femminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3259-x · Cited by 213
Davies, N. M., Kehoe, P. G., Ben-Shlomo, Y., & Martin, R. M. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110347 · Cited by 212
Glucose Transporters in Brain: In Health and in Alzheimer’s Disease
Szablewski, L. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160841 · Cited by 211
Nagai, M., Hoshide, S., & Kario, K. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2009.212 · Cited by 206
Chentli, F., Azzoug, S., & Mahgoun, S. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.167553 · Cited by 202
Fortea, J., Carmona-Iragui, M., Benejam, B., Fernández, S., Videla, L., Barroeta, I., Alcolea, D., Pegueroles, J., Muñoz, L., Belbin, O., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30285-0 · Cited by 201
Molecular Signaling Regulating Endometrium–Blastocyst Crosstalk
Massimiani, M., Lacconi, V., La Civita, F., Ticconi, C., Rago, R., & Campagnolo, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010023 · Cited by 198
Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis
Wood, W. G., Li, L., Müller, W. E., & Eckert, G. P. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12637 · Cited by 194
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002660 · Cited by 193
Madeira, C., Vargas-Lopes, C., Brandão, C. O., Reis, T., Laks, J., Panizzutti, R., & Ferreira, S. T. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00561 · Cited by 193
Chu, C.-S., Tseng, P.-T., Stubbs, B., Chen, T.-Y., Tang, C.-H., Li, D.-J., Yang, W.-C., Chen, Y.-W., Wu, C.-K., Veronese, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24248-8 · Cited by 188 · cited 2×
“In contrast, a novel meta‐analyses, includ‐ ing 55 observational studies from the last 20 years indicated that hydrophilic and lipophilic statins possess the potential to reduce dementia risk [79, 80].”
BackgroundChornenkyy, Y., Wang, W., Wei, A., & Nelson, P. T. (2019) · Brain Pathology · doi:10.1111/bpa.12655 · Cited by 184
Age, vascular health, and Alzheimer disease biomarkers in an elderly sample
Vemuri, P., Lesnick, T. G., Przybelski, S. A., Knopman, D. S., Lowe, V. J., Graff‐Radford, J., Roberts, R. O., Mielke, M. M., Machulda, M. M., Petersen, R. C., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25071 · Cited by 182
Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia
Perluigi, M., & Butterfield, D. A. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/724904 · Cited by 181
Forlenza, O. V., Radanovic, M., Talib, L. L., & Gattaz, W. F. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2019.76 · Cited by 171
Imbalanced cholesterol metabolism in Alzheimer's disease
Xue-shan, Z., Peng, J., Wu, Q., Zhong, R., Li-hong, P., Tang, Z., Jiang, Z., Wang, G., & Liu, L. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.02.024 · Cited by 170
Metabolism: A Novel Shared Link between Diabetes Mellitus and Alzheimer’s Disease
Sun, Y., Ma, C., Sun, H., Wang, H., Peng, W., Zhou, Z., Wang, H., Pi, C., Shi, Y., & He, X. (2020) · Journal of Diabetes Research · doi:10.1155/2020/4981814 · Cited by 170
Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits
Ullrich, C., Pirchl, M., & Humpel, C. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.08.001 · Cited by 169
Target Enzyme in Alzheimer’s Disease: Acetylcholinesterase Inhibitors
Saxena, M., & Dubey, R. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190128125912 · Cited by 162
Matchett, B. J., Grinberg, L. T., Theofilas, P., & Murray, M. E. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02248-1 · Cited by 159
GSK3β and tau protein in Alzheimer's disease and epilepsy
Toral-Rios, D., Pichardo-Rojas, P. S., Alonso-Vanegas, M., & Campos-Peña, V. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00019 · Cited by 158
Hypoxia‐inducible factors as neuroprotective agent in Alzheimer's disease
Ashok, B. S., Ajith, T. A., & Sivanesan, S. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12717 · Cited by 150
Holtzman, D. M. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:147 · Cited by 143
Stamatelopoulos, K. S., Sibbing, D., Rallidis, L. S., Georgiopoulos, G. A., Stakos, D., Braun, S., Gatsiou, A., Sopova, K., Kotakos, C., Varounis, C., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.12.035 · Cited by 134
Nepovimova, E., Korabecny, J., Dolezal, R., Babkova, K., Ondrejicek, A., Jun, D., Sepsova, V., Horova, A., Hrabinova, M., Soukup, O., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01325 · Cited by 128
Association between Use of Statin and Risk of Dementia: A Meta-Analysis of Observational Studies
Poly, T. N., Islam, M. M., Walther, B. A., Yang, H.-C., Wu, C.-C., Lin, M.-C., & Li, Y.-C. (2020) · Neuroepidemiology · doi:10.1159/000503105 · Cited by 128
BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
Maia, M. A., & Sousa, E. (2019) · Pharmaceuticals · doi:10.3390/ph12010041 · Cited by 126
Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S. (2020) · BioMed Research International · doi:10.1155/2020/5120230 · Cited by 121
Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology
Costa, C., Romoli, M., Liguori, C., Farotti, L., Eusebi, P., Bedetti, C., Siliquini, S., Cesarini, E. N., Romigi, A., Mercuri, N. B., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.09.006 · Cited by 120
Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies
Urrestarazu, E., & Iriarte, J. (2016) · Nature and Science of Sleep · doi:10.2147/nss.s76706 · Cited by 117
Paris, D., Bachmeier, C., Patel, N., Quadros, A., Volmar, C.-H., Laporte, V., Ganey, J., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Crawford, F., et al. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00180 · Cited by 114
Carotid Atherosclerosis and Prospective Risk of Dementia
Wendell, C. R., Waldstein, S. R., Ferrucci, L., O’Brien, R. J., Strait, J. B., & Zonderman, A. B. (2012) · Stroke · doi:10.1161/strokeaha.112.672527 · Cited by 110
Verma, S., Kumar, A., Tripathi, T., & Kumar, A. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12919 · Cited by 110
Binding Sites for Amyloid-β Oligomers and Synaptic Toxicity
Smith, L. M., & Strittmatter, S. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024075 · Cited by 109
Cerebrovascular pathology in Down syndrome and Alzheimer disease
Head, E., Phelan, M. J., Doran, E., Kim, R. C., Poon, W. W., Schmitt, F. A., & Lott, I. T. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0499-4 · Cited by 105
Tau-Based Therapeutic Approaches for Alzheimer's Disease - A Mini-Review
Boutajangout, A., & Wisniewski, T. (2014) · Gerontology · doi:10.1159/000358875 · Cited by 103
Gabin, J. M., Tambs, K., Saltvedt, I., Sund, E., & Holmen, J. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0262-x · Cited by 99
Ensemble landmarking of 3D facial surface scans
de Jong, M. A., Hysi, P., Spector, T., Niessen, W., Koudstaal, M. J., Wolvius, E. B., Kayser, M., & Böhringer, S. (2018) · Scientific Reports · doi:10.1038/s41598-017-18294-x · Cited by 95
Epilepsy, amyloid-β, and D1 dopamine receptors: a possible pathogenetic link?
Costa, C., Parnetti, L., D'Amelio, M., Tozzi, A., Tantucci, M., Romigi, A., Siliquini, S., Cavallucci, V., Di Filippo, M., Mazzocchetti, P., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.025 · Cited by 94
Comorbidity and progression of late onset Alzheimer’s disease: A systematic review
Haaksma, M. L., Vilela, L. R., Marengoni, A., Calderón-Larrañaga, A., Leoutsakos, J.-M. S., Olde Rikkert, M. G. M., & Melis, R. J. F. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177044 · Cited by 94
Prevalence, Semiology, and Risk Factors of Epilepsy in Alzheimer’s Disease: An Ambulatory EEG Study
Horváth, A., Szűcs, A., Hidasi, Z., Csukly, G., Barcs, G., & Kamondi, A. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-170925 · Cited by 91
A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents
Appleby, B. S., Nacopoulos, D., Milano, N., Zhong, K., & Cummings, J. L. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000345791 · Cited by 90
Selective serotonin reuptake inhibitors and Alzheimer’s disease
Khoury, R., Mdawar, B., & Ghossoub, E. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.264445 · Cited by 84
Brain arterial aging and its relationship to Alzheimer dementia
Gutierrez, J., Honig, L. S., Elkind, M. S. V., Mohr, J. P., Goldman, J. E., Dwork, A. J., Morgello, S., & Marshall, R. S. (2016) · Neurology · doi:10.1212/wnl.0000000000002590 · Cited by 82
Mao, F., Li, J., Wei, H., Huang, L., & Li, X. (2015) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2014.1003212 · Cited by 80
Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease: A Randomized Trial
de Jong, D. L. K., de Heus, R. A. A., Rijpma, A., Donders, R. A. R. T., Rikkert, M. G. M. O., Günther, M., LAWLOR, B. A., van Osch, M. J. P., & Claassen, J. A. H. R. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12892 · Cited by 80
Paris, D., Quadros, A., Humphrey, J., Patel, N. S., Crescentini, R. M., Crawford, F., & MULLAN, M. J. (2004) · Brain Research · doi:10.1016/j.brainres.2003.11.061 · Cited by 79
Cohen, A. D., McDade, E., Christian, B., Price, J., Mathis, C., Klunk, W., & Handen, B. L. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.002 · Cited by 79
Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?
Hunter, S., & Brayne, C. (2017) · Journal of Negative Results in BioMedicine · doi:10.1186/s12952-017-0066-3 · Cited by 77
Epilepsy and Alzheimer’s Disease: Potential mechanisms for an association
Giorgi, F. S., Saccaro, L. F., Busceti, C. L., Biagioni, F., & Fornai, F. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.04.009 · Cited by 76
Dias, H. K. I., Brown, C. L. R., Polidori, M. C., Lip, G. Y. H., & Griffiths, H. R. (2015) · Clinical Science · doi:10.1042/cs20150351 · Cited by 75
The physical approximation of APP and BACE‐1: A key event in alzheimer's disease pathogenesis
Sun, J., & Roy, S. (2018) · Developmental Neurobiology · doi:10.1002/dneu.22556 · Cited by 75
Karki, R., Kodamullil, A. T., & Hofmann‐Apitius, M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170440 · Cited by 74
Devanand, D. P., Pelton, G. H., D’Antonio, K., Strickler, J. G., Kreisl, W. C., Noble, J., Marder, K., Skomorowsky, A., & Huey, E. D. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000161 · Cited by 73
From here to epilepsy: the risk of seizure in patients with Alzheimer's disease
Nicastro, N., Assal, F., & Seeck, M. (2016) · Epileptic Disorders · doi:10.1684/epd.2016.0808 · Cited by 71
Wharton, W., Stein, J. H., Korcarz, C., Sachs, J., Olson, S. R., Zetterberg, H., Dowling, M., Ye, S., Gleason, C. E., Underbakke, G., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120763 · Cited by 70
Ovchinnikov, D. A., Korn, O., Virshup, I., Wells, C. A., & Wolvetang, E. J. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.05.004 · Cited by 70
Xu, H., Wang, Z., Zhu, L., Sui, Z., Bi, W., Liu, R., Bi, K., & Li, Q. (2018) · Molecules · doi:10.3390/molecules23092375 · Cited by 70
The pharmacology of tacrine at N -methyl- d -aspartate receptors
Hořák, M., Holubová, K., Nepovimová, E., Krůšek, J., Kaniaková, M., Korábečný, J., Vyklický, L., Kuča, K., Stuchlík, A., Říčný, J., et al. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.01.003 · Cited by 69
Type 2 diabetes mellitus in the pathophysiology of Alzheimer's disease
de Nazareth, A. M. (2017) · Dementia & Neuropsychologia · doi:10.1590/1980-57642016dn11-020002 · Cited by 69
Genetic risk for schizophrenia and psychosis in Alzheimer disease
DeMichele-Sweet, M. A. A., Weamer, E. A., Klei, L., Vrana, D. T., Hollingshead, D. J., Seltman, H. J., Sims, R., Foroud, T., Hernandez, I., Moreno-Grau, S., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.81 · Cited by 68
Neuroinflammation in Alzheimer's disease: an understanding of physiology and pathology
Obulesu, M., & Jhansilakshmi, M. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2013.831852 · Cited by 66
Van Dam, D., Vermeiren, Y., D. Dekker, A., J.W. Naudé, P., & P. De Deyn, P. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160502123607 · Cited by 65
Chen, X.-Q., Sawa, M., & Mobley, W. C. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.341 · Cited by 65
Amani, M., Shokouhi, G., & Salari, A. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5137-8 · Cited by 64
Aripiprazole in the treatment of Alzheimer's disease
De Deyn, P. P., Drenth, A. F., Kremer, B. P., Oude Voshaar, R. C., & Van Dam, D. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.764989 · Cited by 61
Alzheimer's disease drug development based on Computer-Aided Drug Design
Zeng, H., & Wu, X. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.039 · Cited by 56
Keri, R. S., Quintanova, C., Chaves, S., Silva, D. F., Cardoso, S. M., & Santos, M. A. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12633 · Cited by 56
Storti, L. B., Quintino, D. T., Silva, N. M., Kusumota, L., & Marques, S. (2016) · Revista Latino-Americana de Enfermagem · doi:10.1590/1518-8345.0580.2751 · Cited by 56
Hospital admissions 2000–2014: A retrospective analysis of 288 096 events in patients with dementia
Bernardes, C., Massano, J., & Freitas, A. (2018) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2018.05.006 · Cited by 54
Barone, E., Head, E., Butterfield, D. A., & Perluigi, M. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.10.508 · Cited by 53
Cholesterol and Alzheimer's disease: A still poorly understood correlation
Ricciarelli, R., Canepa, E., Marengo, B., Marinari, U. M., Poli, G., Pronzato, M. A., & Domenicotti, C. (2012) · IUBMB Life · doi:10.1002/iub.1091 · Cited by 49
Neurovascular and Cognitive failure in Alzheimer’s Disease: Benefits of Cardiovascular Therapy
Hamel, É., Royea, J., Ongali, B., & Tong, X. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0285-4 · Cited by 47
Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome
D. Hamlett, E., A. Boger, H., Ledreux, A., M. Kelley, C., J. Mufson, E., F. Falangola, M., N. Guilfoyle, D., A. Nixon, R., Patterson, D., Duval, N., et al. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150921095505 · Cited by 46
1H-MRS metabolites in adults with Down syndrome: Effects of dementia
Lin, A.-L., Powell, D., Caban-Holt, A., Jicha, G., Robertson, W., Gold, B. T., Davis, R., Abner, E., Wilcock, D. M., Schmitt, F. A., et al. (2016) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.06.001 · Cited by 44
Tau Related Pathways as a Connecting Link between Epilepsy and Alzheimer’s Disease
Paudel, Y. N., Angelopoulou, E., Jones, N. C., O'Brien, T. J., Kwan, P., Piperi, C., Othman, I., & Shaikh, M. F. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00460 · Cited by 44
Kennedy, J., Deberdt, W. G., Siegal, A. P., Micca, J. L., Degenhardt, E. K., AHL, J. S. B., Meyers, A. L., Kaiser, C. J., & Baker, R. W. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1397 · Cited by 42
Dissecting Alzheimer disease in Down syndrome using mouse models
Choong, X. Y., Tosh, J. L., Pulford, L. J., & Fisher, E. M. C. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00268 · Cited by 42
Paul, K. C., Jerrett, M., & Ritz, B. R. (2018) · Current Environmental Health Reports · doi:10.1007/s40572-018-0176-1 · Cited by 42
Comorbid Sleep Disturbances in Neurologic Disorders
Ju, Y. S., Videnović, A., & Vaughn, B. V. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000501 · Cited by 41
Szymański, P., Markowicz-Piasecka, M., & Mikiciuk‐Olasik, E. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.05.001 · Cited by 40
Self-citationAPOE genetic variants and apoE, miR-107 and miR-650 levels in Alzheimer’s disease
Prendecki, M., Florczak-Wyspianska, J., Kowalska, M., Ilkowski, J., Grzelak, T., Bialas, K., Kozubski, W., & Dorszewska, J. (2019) · Folia Neuropathologica · doi:10.5114/fn.2019.84828 · Cited by 40
The relationship between cholesterol and cognitive function is homocysteine-dependent
Gao, S., Cheng, Y., Jin, Y., Unverzagt, F. W., Su, L., Yang, L., Ma, F., Hake, A. M., Kettler, C. D., Chen, C., et al. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s64766 · Cited by 39
Idahl, A., Darelius, A., Sundfeldt, K., Pålsson, M., & Strandell, A. (2019) · Trials · doi:10.1186/s13063-018-3083-8 · Cited by 37
Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review
Rampa, A., Gobbi, S., Martino, R. M. C. D., Belluti, F., & Bisi, A. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180112161406 · Cited by 35
Hypertension and Alzheimer Disease: Another Brick in the Wall of Awareness
Thorin, É. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.04257 · Cited by 34
Epilepsy in patients with Alzheimer's disease: A systematic review
Miranda, D. D. C., & Brucki, S. M. D. (2014) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642014dn81000010 · Cited by 32
Milenković, I., Jarc, J., Dassler, E., Aronica, E., Iyer, A. M., Adle‐Biassette, H., Scharrer, A., Reischer, T., Hainfellner, J. A., & Kovács, G. G. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12406 · Cited by 32
Ogama, N., Sakurai, T., Kawashima, S., Tanikawa, T., Tokuda, H., Satake, S., Miura, H., Shimizu, A., Kokubo, M., Niida, S., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00273 · Cited by 32
Genetics of psychosis of Alzheimer disease
Shah, C., DeMichele‐Sweet, M. A. A., & Sweet, R. A. (2016) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32413 · Cited by 31
Chen, Y., Liu, Z., Fu, T., Li, W., Xu, X., & Sun, H.-P. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.026 · Cited by 30
Oh, H., Steffener, J., Razlighi, Q. R., Habeck, C., & Stern, Y. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3266-15.2016 · Cited by 30
Gholipour, T., Mitchell, S. B., Sarkis, R. A., & Chemali, Z. N. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.12.014 · Cited by 30
Bajda, M., Jończyk, J., Malawska, B., Czarnecka, K., Girek, M. K., Olszewska, P., Sikora, J., Mikiciuk‐Olasik, E., Skibiński, R., Gumieniczek, A., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.07.029 · Cited by 29
Self-citationOptimal treatment of Alzheimer’s disease psychosis: challenges and solutions
Koppel, J. L., & GREENWALD, B. S. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s60837 · Cited by 29
Signs indicating dementia in Down, Williams and Fragile X syndromes
Sauna‐aho, O., Bjelogrlic‐Laakso, N., Sirén, A., & Arvio, M. (2018) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.430 · Cited by 29
Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer’s disease
Cretin, B. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1496237 · Cited by 29
High blood pressure, Alzheimer disease and antihypertensive treatment
Marfany, A., Sierra, C., Camafort, M., Doménech, M., & Coca, A. (2018) · Panminerva Medica · doi:10.23736/s0031-0808.18.03360-8 · Cited by 29
Incident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimer’s Disease
Weamer, E. A., DeMichele‐Sweet, M. A. A., Cloonan, Y. K., López, O. L., & Sweet, R. A. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10617 · Cited by 28
Flores-Martínez, E., & Peña‐Ortega, F. (2017) · International Journal of Peptides · doi:10.1155/2017/7386809 · Cited by 28 · cited 1×
“It has been reported that the development of AD is associated with the deposition of plaques in grey matter caused by β‐amyloid aggregation and subsequent polymerization to insoluble fibrils [21].”
BackgroundSchipke, C. G., De Vos, A., Fuentes, M., Jacobs, D., Vanmechelen, E., & Peters, O. (2018) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000489847 · Cited by 27
Alzheimer's Disease and Its Potential Alternative Therapeutics.
Kisby, B. R., Jarrell, J. T., Me, A., Ds, C., Er, R., Cm, C., Rogers, J. T., & Huang, X. (2019) · PubMed · doi:10.4172/2161-0460.1000477 · Cited by 27
Cenini, G., Fiorini, A., Sultana, R., Perluigi, M., Cai, J., Klein, J. B., Head, E., & Butterfield, D. A. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.08.006 · Cited by 26
Ettcheto, M., Petrov, D., Pedrós, I., de Lemos, L., Pallàs, M., Alegret, M., Laguna, J. C., Folch, J., & Camins, A. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.03.010 · Cited by 26
Mattoso, A. A. A., Tsutsui, J. M., Kowatsch, I., Cruz, V. Y. L., Sbano, J., Ribeiro, H. B., Filho, R. K., Porter, T. R., & Mathias, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172280 · Cited by 26
Abdullah, L. I., Crawford, F., Tsolaki, M., Börjesson‐Hanson, A., Rikkert, M. G. M. O., Pasquier, F., Wallin, A., Kennelly, S., Ait‐Ghezala, G., Paris, D., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00149 · Cited by 26
Szabo‐Reed, A. N., Vidoni, E. D., Binder, E. F., Burns, J. M., Cullum, C. M., Gahan, W. P., Gupta, A., Hynan, L. S., Kerwin, D. R., Rossetti, H. C., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.02.007 · Cited by 25
Epilepsy in neuropathologically verified Alzheimer’s disease
Rauramaa, T. H., Saxlin, A., Lohvansuu, K., Alafuzoff, I. I., Pitkänen, A., & Soininen, H. S. (2018) · Seizure · doi:10.1016/j.seizure.2018.03.014 · Cited by 24
The overlap between epilepsy and Alzheimer’s disease and the consequences for treatment
Powell, G. A., Ziso, B., & Larner, A. J. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1629289 · Cited by 24
Role of metal ions in the cognitive decline of Down syndrome
Malakooti, N., Pritchard, M. A., Adlard, P. A., & Finkelstein, D. I. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00136 · Cited by 23
Cracking novel shared targets between epilepsy and Alzheimer’s disease: need of the hour
Garg, N., Joshi, R., & Medhi, B. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0064 · Cited by 23
Nday, C. M., Eleftheriadou, D., & Jackson, G. E. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14256 · Cited by 22
Head, E., Powell, D. K., & Schmitt, F. A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00191 · Cited by 22
Association between the characteristics of metabolic syndrome and Alzheimer’s disease
Yang, H.-T., Sheen, Y., Kao, C.-D., Chang, C.-A., Hu, Y.-C., & Lin, J.-L. (2013) · Metabolic Brain Disease · doi:10.1007/s11011-013-9406-2 · Cited by 21
Neulen, A., Kunzelmann, S., Kosterhon, M., Pantel, T., Stein, M., Berres, M., Ringel, F. A., Brockmann, M. A., Brockmann, C., & Kantelhardt, S. R. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00013 · Cited by 21
Girard, H., Potvin, O., Nugent, S., Dallaire‐Théroux, C., Cunnane, S. C., & Duchesne, S. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.11.013 · Cited by 20
Wang, X., Xiong, Y., Yang, Y., Tuo, Q., Wang, X., Chen, R., Tian, Q., Zhang, Z.-P., Yan, X., Yang, Z.-Y., et al. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.022 · Cited by 19
Arslan, A., Tüzün, F. A., Arslan, H., Demir, H., Tamer, S., Demir, C., & Taşin, M. (2016) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2016.07.002 · Cited by 19
Zhang, Q., Ling, S., Li, P., Zhang, S., Ng, C. H., Ungvari, G. S., Wang, L., Lee, S.-Y., Wang, G., & Xiang, Y. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.25000 · Cited by 18
Montoya, J. C., Fajardo, D., Peña, Á., Sánchez, A., Domínguez, M. C., Satizábal, J. M., & Vallejo, F. G. (2014) · Colombia medica · doi:10.25100/cm.v45i4.1640 · Cited by 17
Bahety, P., Nguyen, T. H. V., Hong, Y., Zhang, L., Chan, E. C. Y., & Ee, P. L. R. (2015) · Zeitschrift für Ernährungswissenschaft · doi:10.1007/s00394-015-1053-4 · Cited by 15
Vibrational spectroscopy: a promising approach to discriminate neurodegenerative disorders
Paraskevaidi, M., Martin‐Hirsch, P. L., & Martin, F. L. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0252-x · Cited by 15
Hu, S., Wang, R., Cui, W., Mak, S., Li, G., Yuanjia, H., Lee, M., Pang, Y., & Han, Y. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12472 · Cited by 14
Role of Vascular Disease in Alzheimer-Like Progressive Cognitive Impairment
Viswanathan, A., Greenberg, S. M., & Scheltens, P. (2015) · Stroke · doi:10.1161/strokeaha.115.009010 · Cited by 10
Incidence of sleep disorders in patients with Alzheimer disease
Camargos, E. F., Pandolfi, M. B., Dias, M. P., Quintas, J. L., Guimarães, R. M., & Nóbrega, O. D. T. (2011) · Einstein (São Paulo) · doi:10.1590/s1679-45082011ao2145 · Cited by 9
Koppel, J. L., Sousa, A., Gordon, M. L., Giliberto, L., Christen, E., & Davies, P. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.0482 · Cited by 9
Down syndrome, increased risk of dementia and lipid disturbances.
Kłosowska, A., Ćwiklińska, A., Kuchta, A., Berlińska, A., Jankowski, M., & Wierzba, J. (2017) · PubMed Central · doi:10.34763/devperiodmed.20172101.6973 · Cited by 9 · cited 1×
“People with DS are frequently affected by congenital heart diseases, hypothyroidism, hyperlipidemia and hypercho‐ lesterolemia, obesity, and insulin resistance [119].”
BackgroundDown syndrome: From development to adult life to Alzheimer disease
Butterfield, D. A., & Marzia Perluigi, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.374 · Cited by 5
Mess, E., Witkowicz, M., Ornat, M., Sielski, P., & Klaszczyk, T. (2018) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2018.03.008 · Cited by 3
Down syndrome cognitive marker's significance in Alzheimer's disease and dementia management
Mahla, R. S. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.04.010 · Cited by 1
(2012) · PubMed
Research works printed but not linked: 1
- Lawlor B Segurado R Kennelly S Rikkert M Howard R Pasquier F Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial PLoS Med 2018 15 9 20 PMC6152871 30248105 · DOI · Paper page
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“Currently, antibodies like aducanumab ( 1 ), lecanemab ( 2 ), and donanemab ( 10 ) show their promise in proving A β as a signi fi cant factor in AD development.”
BackgroundStress-Induced Depression and Alzheimer’s Disease: Focus on Astrocytes
Dolotov, O. V., Inozemtseva, L. S., Myasoedov, N. F., & Grivennikov, I. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094999 · Cited by 110
“It is assumed that the desensitization of GR is an important cause of both HPAA deregulation and activation of the immune system [37,41], although there is no correlation between inflammation and glucocorticoid resistance in patients [54].”
BackgroundAlzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
Vogt, A.-C. S., Jennings, G. T., Mohsen, M. O., Vogel, M., & Bachmann, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043895 · Cited by 84
“The effects of comorbidities are particularly important in AD patients as most of them have at least one comorbid condition [17].”
BackgroundAdewuyi, E. O., O’Brien, E. K., Nyholt, D. R., Porter, T., & Laws, S. M. (2022) · Communications Biology · doi:10.1038/s42003-022-03607-2 · Cited by 83
AbouElhassan, K. M., Sarhan, H. A., Hussein, A. K., Taye, A., Ahmed, Y. M., & Safwat, M. A. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s381353 · Cited by 45
“Acetylcholine (ACh) is the primary cholinergic neurotransmitter synthesis in the central neurons responsible for maintaining consciousness, recognition, thinking, and learning, especially in the basal forebrain, frontal lobe, hippocampus, and brainstem.(14,15) Decreased Ach levels in the brain significantly characteri…”
Background
Metadata
- Authors
- Maciejewska, K., Czarnecka, K., & Szymański, P.
- Affiliations
- Medical University of Lodz (PL)
- Corresponding author
- Szymański, Paweł
- Venue
- Pharmacological Reports
- Published
- 2021-06-13
- Volume
- 73
- Issue
- 6
- Pages
- 1565-1581
- ISSN
- 1734-1140 (ISSN-L)
- 2299-5684
- PMC
- PMC8599320
- OpenAlex
- W3171782439
- Cited by
- 64
- References
- 176
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 11 · 2023: 10 · 2022: 12 · 2021: 2
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Pharmacological Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Narodowym Centrum Nauki (2015/19/B/NZ7/02847)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, comorbidities, hypercholesterolemia, hypertension, atherosclerosis, diabetes mellitus, psychosis, sleep disorders, epilepsy, depression, Down syndrome, drug repurposing, pharmacotherapy, pathogenesis
- MeSH terms
- Drug Development, Aged, Alzheimer Disease, Animals, Humans, Risk Factors, Disease Progression, Drug Repositioning, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
